Research suggests that NDUFA4L2 plays a role in the progression and chemotherapy sensitivity of head and neck squamous cell carcinoma, possibly by inhibiting PANoptosis. However, its role in cancer progression may be complex, as it has also been linked to promoting glioblastoma progression. The relationship between NDUFA4L2 and cancer treatment outcomes is still being studied, with various mechanisms and potential targets being explored.